Navidea Biopharmaceuticals, Inc.
NAVB · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $6,162 | $29,344 | $51,376 | $18,136 |
| - Cash | $1,996 | $4,231 | $2,670 | $1,047 |
| + Debt | $2,436 | $749 | $1,336 | $1,069 |
| Enterprise Value | $6,602 | $25,862 | $50,042 | $18,157 |
| Revenue | $66 | $532 | $915 | $27 |
| % Growth | -87.6% | -41.9% | 3,337.6% | – |
| Gross Profit | -$170 | $333 | $914 | $20 |
| % Margin | -259.4% | 62.6% | 99.9% | 75% |
| EBITDA | -$13,983 | -$11,507 | -$10,641 | -$10,818 |
| % Margin | -21,298.7% | -2,164.9% | -1,162.9% | -40,641.7% |
| Net Income | -$15,177 | -$11,731 | -$10,722 | -$10,946 |
| % Margin | -23,117.6% | -2,207.1% | -1,171.8% | -41,120.9% |
| EPS Diluted | -0.56 | -0.4 | -0.48 | -0.76 |
| % Growth | -40% | 16.7% | 36.8% | – |
| Operating Cash Flow | -$8,987 | -$10,218 | -$8,174 | -$9,355 |
| Capital Expenditures | -$390 | -$329 | -$414 | -$57 |
| Free Cash Flow | -$9,377 | -$10,548 | -$8,588 | -$9,411 |